Esophageal varix
Conditions
Interventions
Using propofol for sedation during endoscopic injection sclerotherapy
Using midazolam for sedation during endoscopic injection sclerotherapy
Sponsors
Department of Endoscopy, Fukushima Medical University Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Patient with liver cirrhosis who will be prophylactically performed endoscopic injection sclerotherapy for esophageal varix. 2.ECOG-Performance Status is 0 or1. 3. Patient without overtminimal hepatic encephalopathy. 4. Patient must provide written consent to participate in the study. 5. Patient without allergy to propofol and midazolam.
Exclusion criteria
Exclusion criteria: 1. Patients with an American Society of Anesthesiologists (ASA) physical status of class 3, 4, 5. 2. Patients with active variceal bleeding. or past variceal bleeding. 3. Recurrent case after the treatment for esopageal varices. 4. Patients with severe liver failure(T.bil 4mg/gl, Child-Pugh score C). 5. Patients with severe renal failure. 6. Patients with overtminimal hepatic encephalopathy. 7. Patients with dementia, psychiatric illness. 8. Patient with comsumption of neuroactive medication. 9. Patient with drug abuse. 10. Patient with ongoing alcohol comsumption 2 weeks before the tratment. 11. Patient with allergy to propofol and midazolam. 12. Patient who have been judged as psychotic manifestation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| minimal hepatic encephalopathy after endoscopic injection sclerotherapy | — |
Countries
Japan
Contacts
Public ContactKo Watanabe
Fukushima Medical University Hospital Department of Endoscopy
Outcome results
None listed